# Monitoring Endocrine Therapy in Veterinary Patients: Insulin and Beyond
## Key Takeaways
- Monitoring endocrine therapy, particularly insulin and thyroid hormone replacement, necessitates a structured, cyclical approach integrating clinical response, laboratory data (e.g., blood glucose curves, fructosamine, total T4), and owner observations to guide dose adjustments and differentiate treatment failure.
- The blood glucose nadir (target 100-200 mg/dL) and duration of insulin effect are critical decision points for dose adjustment, with nadirs below 80 mg/dL triggering a dose reduction and insufficient duration requiring formulation or dosing interval changes.
- Fructosamine provides a 2-3 week average of glycemia and is particularly useful in cats to assess overall control, but it cannot detect hypoglycemia, necessitating correlation with clinical signs and glucose curves.
- Thyroid hormone replacement monitoring in dogs involves measuring total T4 4-6 hours post-dose to ensure levels are within or slightly above the reference interval, with rechecks at 2-4 weeks initially and then every 3-6 months.
- Continuous glucose monitoring (CGM) offers detailed interstitial glucose trends and variability, proving valuable for detecting nocturnal hypoglycemia and reducing patient stress, though it requires calibration against blood glucose measurements.
- Documenting all monitoring encounters, including insulin dose, injection details, laboratory results, and owner-reported signs, is crucial for detecting trends, identifying complications like Somogyi effect or hypersomatotropism, and ensuring continuity of care.
---
Endocrine therapy monitoring in dogs and cats requires a structured approach that balances clinical response, laboratory endpoints, and owner-reported observations. This article provides a procedural framework for monitoring insulin therapy in diabetic patients and extends that framework to thyroid hormone replacement, with emphasis on the decision logic that distinguishes dose adjustment from treatment failure. It is written for veterinary students and practitioners who need a practical, evidence-informed reference for day-to-day case management.
The central question this article answers is straightforward: how does the clinician know whether an endocrine therapy is working, and what action follows from each possible answer? Monitoring is not a single test but a recurring cycle of measurement, interpretation, and adjustment. The parameters chosen, the intervals between assessments, and the thresholds that trigger intervention differ by drug, species, and disease state. Understanding the underlying pharmacology and pathophysiology is therefore a prerequisite for interpreting any monitoring result.
## At a Glance
| Parameter | Species | Monitoring Goal | Decision Trigger |
|---|---|---|---|
| Blood glucose curve | Dog, cat | Identify nadir, duration of effect, and peak action | Nadir below target or duration shorter than expected |
| Fructosamine | Dog, cat | Assess average glycemia over 2 to 3 weeks | Persistent elevation despite dose adjustment |
| Continuous glucose monitoring | Cat | Capture interstitial glucose trends and variability | Recurrent hypoglycemia or unexplained clinical signs |
| Clinical signs (polyuria, polydipsia, appetite) | Dog, cat | Correlate owner observations with laboratory data | Worsening signs despite stable glucose readings |
| Body weight | Dog, cat | Detect insulin resistance or over-insulinisation | Unexplained gain or loss exceeding 5% |
| Total T4 | Dog | Confirm adequate thyroid hormone replacement | Value outside reference interval at trough |
| Free T4 by equilibrium dialysis | Dog | Resolve ambiguous total T4 results | Discordance between total T4 and clinical response |
| Urine glucose and ketones | Dog, cat | Screen for poor control or impending ketoacidosis | Persistent glucosuria or any ketonuria |
## Principles of Endocrine Therapy Monitoring
Endocrine therapies replace, suppress, or mimic endogenous hormone action. The therapeutic window is often narrow because the target hormone participates in tightly regulated feedback loops. Monitoring therefore serves three distinct purposes: confirming that the drug reaches its target, verifying that the target responds appropriately, and detecting adverse effects before they become clinically apparent.
The pharmacokinetic properties of the drug determine the timing of measurements. Insulin preparations differ in onset, peak, and duration, so a blood glucose curve must be interpreted against the expected action profile of the specific product used. The same principle applies to thyroid hormone replacement, where the timing of blood sampling relative to medication administration is critical for interpreting total T4 concentrations.
A second principle is that no single measurement is sufficient. Clinical signs, physical examination findings, and laboratory data must be integrated. The [iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats](https://pubmed.ncbi.nlm.nih.gov/41224734/) emphasize a team approach involving veterinary professionals and the caregiver, reflecting the reality that owner observations often detect problems before laboratory values change.
## Physiology of Glucose Homeostasis and Insulin Action
Insulin secretion from pancreatic beta-cells is the primary anabolic signal in the body. It promotes glucose uptake in muscle and adipose tissue, suppresses hepatic gluconeogenesis, and stimulates glycogen synthesis. In diabetic patients, the balance between insulin supply and tissue demand determines the degree of hyperglycemia and the risk of hypoglycemia.
The islets of Langerhans are the functional unit of this system. Research on peptide-mediated targeting of the islets of Langerhans has demonstrated that beta-cell function can be assessed by the ability of these cells to respond to glucose stimulation, and that dysfunctional beta-cells lose this responsiveness. This distinction between functional and dysfunctional beta-cells has direct clinical relevance: a diabetic cat that retains some beta-cell function may achieve remission, while a cat with complete beta-cell failure will require lifelong insulin therapy.
In cats, diabetes mellitus is predominantly type 2, resulting from peripheral insulin resistance combined with progressive reduction in insulin production. This pathophysiology explains why some cats respond to oral hypoglycemic agents and why remission is attainable in a majority of newly diagnosed diabetic cats when glycemia is controlled early and aggressively. The [clinical use of long-acting glargine and detemir in feline diabetes](https://pubmed.ncbi.nlm.nih.gov/24563492/) is based on this understanding: long-acting insulin analogues provide a steady basal insulin level that suppresses hepatic glucose output without causing sharp peaks that risk hypoglycemia.
## Pharmacological Basis of Monitoring Intervals
The duration of action of an insulin preparation dictates the minimum interval between dose adjustments. Short-acting insulins require frequent glucose measurements, while long-acting preparations allow less intensive monitoring. However, the clinical response to a dose change is not immediate. Steady-state glycemia may take several days to emerge, and adjusting doses more frequently than the drug's duration of action invites cumulative error.
For thyroid hormone replacement, the situation is different. Levothyroxine has a relatively short half-life in dogs, and serum T4 concentrations fluctuate predictably after oral administration. Monitoring must therefore be timed to capture the trough concentration, which reflects the lowest hormone level the patient experiences between doses.
The choice of monitoring tool also affects the interval. Intermittent blood glucose curves provide a snapshot, while continuous glucose monitoring devices generate a detailed picture of glucose variability over days. The [iCatCare consensus guidelines](https://pubmed.ncbi.nlm.nih.gov/41224734/) note that increased use of continuous glucose monitoring has provided more detailed information on affected cats, allowing clinicians to detect patterns that would be missed by isolated measurements.
## Interpreting the Blood Glucose Curve
A blood glucose curve is the foundation of insulin monitoring. The curve plots glucose concentrations over a 12 to 24 hour period, typically with measurements every 2 hours. The key features are the nadir, the time to nadir, the duration of glucose concentrations below the renal threshold, and the peak glucose concentration.
The nadir is the most important safety parameter. It identifies the point of maximum insulin action and the moment when hypoglycemia is most likely. The time to nadir indicates whether the insulin preparation is acting as expected. A nadir that occurs earlier than expected suggests the insulin is peaking too quickly, while a nadir that occurs later suggests delayed absorption or an inappropriate preparation choice.
The duration of action is assessed by the interval between insulin administration and the return of glucose to baseline. If glucose concentrations rise above the renal threshold before the next dose is due, the insulin is not providing adequate coverage. Conversely, if glucose concentrations remain low at the time of the next dose, the insulin duration may be too long, and the dose should be reduced.
## Fructosamine and Glycated Proteins
Fructosamine is a glycated protein that reflects average glucose concentrations over the preceding 2 to 3 weeks. It is particularly useful in cats, where stress hyperglycemia can confound single glucose measurements. Fructosamine does not replace the glucose curve, but it provides a complementary view of overall glycemic control.
The interpretation of fructosamine requires knowledge of the reference interval for the laboratory performing the assay. A value within the reference interval suggests adequate control, while a value above the reference interval indicates persistent hyperglycemia. However, fructosamine cannot distinguish between frequent hypoglycemia and stable normoglycemia, because both produce similar average glucose concentrations. This limitation is clinically significant: a cat with recurrent hypoglycemia may have a normal or even low fructosamine, and the clinician must rely on clinical signs and glucose curves to detect the problem.
## Monitoring for Adverse Effects
Hypoglycemia is the most serious adverse effect of insulin therapy. Clinical signs include lethargy, weakness, ataxia, tremors, and seizures. The threshold for clinical signs varies between patients, and some animals tolerate glucose concentrations that would cause signs in others. Owner education is therefore a component of monitoring, and the [AVMA practice resources](https://www.avma.org/resources-tools) provide guidance on client communication and emergency preparedness.
Weight loss in a diabetic patient receiving insulin may indicate inadequate caloric intake, poor absorption, or an underlying comorbidity. Weight gain, particularly in cats, may indicate over-insulinisation. Serial body weight measurements are simple, inexpensive, and often overlooked in monitoring protocols.
## Species Differences in Monitoring Approach
Dogs and cats differ in their response to insulin therapy and in the monitoring tools that are most useful. Dogs with diabetes mellitus are typically insulin-dependent and require lifelong therapy. Cats, by contrast, may achieve remission, and the monitoring protocol must be designed to detect remission early so that insulin can be reduced or discontinued before hypoglycemia develops.
The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific reference intervals and monitoring recommendations that reflect these differences. The clinician should consult these resources when establishing a monitoring protocol for an individual patient, and should adjust the protocol based on the patient's response.
## Limitations of Current Monitoring Tools
No single monitoring tool provides a complete picture of endocrine therapy efficacy. Blood glucose curves are labor-intensive and capture only a single day. Fructosamine reflects average glycemia but cannot detect hypoglycemia. Continuous glucose monitoring provides detailed data but requires specialised equipment and owner compliance.
The evidence base for some monitoring strategies is limited. Comparative studies of different monitoring protocols are scarce, and much of the clinical guidance is extrapolated from human medicine or from expert opinion. The [Davis-Thompson Foundation veterinary pathology resources](https://www.davisthompsonfoundation.org/) offer case material that can help students and practitioners recognize the pathologic consequences of poorly monitored endocrine therapy, but these resources do not replace prospective clinical studies.
Clinicians should acknowledge this uncertainty when designing monitoring protocols and should be prepared to adapt their approach based on individual patient responses.
## Structured Monitoring Schedules for Insulin Therapy
A monitoring schedule should be established at diagnosis and revised at each recheck. The schedule must balance diagnostic yield against client burden and patient stress. For diabetic cats, the iCatCare 2025 consensus guidelines emphasize a team approach involving veterinary professionals and the caregiver, as this is likely to optimize patient outcomes [iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats](https://pubmed.ncbi.nlm.nih.gov/41224734/).
### Initial Stabilization Phase
During the first 2 to 4 weeks after diagnosis or after any insulin formulation change, schedule rechecks every 7 to 14 days. Each recheck should include a blood glucose curve, body weight measurement, body condition score, and a structured owner interview covering water intake, urine output, appetite, and activity level.
The first curve after starting insulin serves primarily to detect hypoglycemia and to establish the direction of dose adjustment. Do not expect a therapeutic curve at this stage. If the cat is receiving glargine or detemir, the duration of action may exceed 12 hours, and a 12-hour curve may not capture the nadir or the full duration of effect [Feline diabetes mellitus: clinical use of long-acting glargine and detemir](https://pubmed.ncbi.nlm.nih.gov/24563492/). Extend the curve to 14 to 16 hours when feasible, or use intermittent glucose measurements across a 24-hour period.
### Maintenance Phase
Once clinical signs are controlled and glucose curves show acceptable patterns, extend the recheck interval to 4 to 8 weeks. Stable patients on a fixed dose can be reassessed every 3 to 4 months with a fructosamine measurement, body weight, and owner questionnaire. A full glucose curve should be repeated at least every 3 months, or sooner if clinical signs change.
The following table provides a monitoring schedule framework. Adjust intervals based on patient stability, client capability, and available equipment.
| Phase | Frequency | Core parameters | Dose adjustment trigger |
|---|---|---|---|
| Initial stabilization | Every 7 to 14 days | Blood glucose curve, body weight, clinical signs | Nadir below target range, clinical hypoglycemia, or lack of response after 7 days |
| Early maintenance | Every 2 to 4 weeks | Blood glucose curve, fructosamine, body weight | Persistent polyuria or polydipsia, weight loss, or nadir outside target |
| Established maintenance | Every 1 to 3 months | Fructosamine, body weight, owner questionnaire | Fructosamine rising or falling out of reference interval, weight change |
| Long-term stable | Every 3 to 4 months | Fructosamine, body weight, clinical signs | Any change in appetite, thirst, or body weight |
## Decision Points in Dose Adjustment
The blood glucose nadir is the primary decision point for insulin dose changes. For most dogs and cats, the target nadir is between 100 and 200 mg/dL (5.5 to 11.1 mmol/L), though the specific target varies with the insulin formulation and the individual patient. A nadir below 80 mg/dL (4.4 mmol/L) warrants a dose reduction of 10 to 25 percent, even in the absence of observed clinical hypoglycemia.
The duration of insulin effect is the second decision point. If glucose rises above 250 mg/dL (13.9 mmol/L) before the next scheduled dose, the duration of action is insufficient. Options include increasing the dose, switching to a longer-acting formulation, or adjusting the dosing interval. For cats, long-acting insulins such as glargine and detemir are preferred because they more closely mimic basal insulin secretion and are associated with higher remission rates [Feline diabetes mellitus: clinical use of long-acting glargine and detemir](https://pubmed.ncbi.nlm.nih.gov/24563492/).
The glucose curve pattern also informs the adjustment. A curve with a flat, elevated profile suggests underdosing or poor absorption. A curve with a rapid drop followed by a rapid rise suggests the insulin is peaking too quickly, which may indicate the need for a different formulation or a change in injection site. A curve with a prolonged nadir and slow return to baseline suggests the dose is too high or the insulin duration is longer than the dosing interval.
## Monitoring Thyroid Hormone Replacement
For dogs receiving levothyroxine replacement, monitoring centers on serum total T4 concentration measured 4 to 6 hours after the morning dose. The target is a T4 within or slightly above the reference interval. Sampling at the same time point at each recheck is essential because the post-pill peak varies with the formulation and the individual patient.
Recheck T4 at 2 to 4 weeks after starting therapy or after any dose change. Once stable, recheck every 3 to 6 months. Clinical response, including activity level, skin and coat quality, and body weight, should be assessed at each visit. The MSD Veterinary Manual provides species-specific reference intervals and monitoring guidance for thyroid hormone therapy [MSD Veterinary Manual professional reference](https://www.msdvetmanual.com/).
For cats receiving methimazole for hyperthyroidism, monitoring includes total T4, renal parameters, and a complete blood count. The T4 should be measured 2 to 4 weeks after starting therapy or after a dose change, then every 3 to 6 months once stable. Renal function must be reassessed after euthyroidism is achieved because pre-existing renal disease may become clinically apparent.
## Continuous Glucose Monitoring in Practice
Continuous glucose monitoring (CGM) devices have changed how glucose curves are obtained in veterinary patients. These sensors measure interstitial glucose concentration and transmit data to a receiver or smartphone application. The iCatCare guidelines note that CGM use has increased and provides more detailed information on affected cats [iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats](https://pubmed.ncbi.nlm.nih.gov/41224734/).
CGM is particularly useful for detecting nocturnal hypoglycemia, which is often missed on a 12-hour in-hospital curve. It also reduces the stress of repeated venepuncture, which can itself affect glucose readings. However, CGM readings lag behind blood glucose by 5 to 15 minutes, and the sensors must be calibrated against blood glucose measurements according to the manufacturer's instructions.
The choice between CGM and serial blood glucose measurement depends on equipment availability, client finances, and the specific clinical question. CGM is preferred when hypoglycemia is suspected, when the curve pattern is erratic, or when the patient is difficult to handle. Serial blood glucose measurement remains appropriate for routine rechecks and when CGM is not available.
## Documentation and Record Keeping
Every monitoring encounter should produce a structured record that includes the date, the insulin formulation and dose, the route and site of injection, the glucose curve data or CGM trace, the fructosamine result, body weight, and a summary of clinical signs. The record should also note any dose changes made and the rationale for those changes.
Serial records allow the clinician to detect trends that a single recheck cannot reveal. A gradual rise in fructosamine over several months may indicate declining insulin sensitivity, intercurrent disease, or problems with insulin storage or administration. A gradual decline in body weight despite adequate glucose control should prompt investigation for concurrent disease, including hypersomatotropism in cats [iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats](https://pubmed.ncbi.nlm.nih.gov/41224734/).
The record should also document owner-reported observations, including episodes of hypoglycemia, changes in appetite, and any difficulties with insulin administration. These details often provide the first indication of a problem that laboratory testing has not yet detected.
## Recognized Complications and Early Detection
The most common failure mode in insulin therapy is hypoglycemia, which may present as lethargy, ataxia, seizures, or sudden collapse. Early detection relies on owner observation of behavior change between meals and on structured glucose measurement. In cats, the 2025 iCatCare consensus guidelines emphasize that clinical signs of hypoglycemia should trigger immediate dose reduction even before confirmatory glucose testing, because the risk of neuroglycopenia outweighs the risk of transient hyperglycemia [iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats](https://pubmed.ncbi.nlm.nih.gov/41224734/).
Somatogyi effect, or rebound hyperglycemia, follows an unrecognised hypoglycemic episode and produces a blood glucose curve that appears to show insulin resistance. The discriminating finding is a curve with a nadir below the reference range followed by a sharp rise to high values. A single pre-insulin glucose measurement will not detect this pattern. Only a full curve, or a continuous glucose monitoring trace, reveals the sequence.
Persistent hyperglycemia without hypoglycemic episodes points toward underdosing, poor insulin handling, injection technique error, or intercurrent disease. In cats, hypersomatotropism is a prevalent underlying cause of insulin resistance and should be suspected when insulin requirements escalate progressively despite adequate monitoring [iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats](https://pubmed.ncbi.nlm.nih.gov/41224734/). Concurrent conditions such as pancreatitis, urinary tract infection, dental disease, and hyperthyroidism in cats or hyperadrenocorticism in dogs will blunt insulin response until treated.
Diabetic ketoacidosis remains the most urgent complication. Early warning signs include anorexia, vomiting, lethargy, and progressive hyperglycemia with ketonuria. Home urine ketone testing is useful in cats when glucose readings exceed 20 mmol/L, because diabetic cats may develop ketosis rapidly. Hospitalization and intensive care are indicated when ketonemia is confirmed.
## Common Errors and Corrective Actions
Less experienced clinicians frequently adjust insulin doses on the basis of a single glucose measurement. A single reading reflects only one point in time and cannot distinguish between inadequate dose, excessive dose with rebound, or poor timing of the curve. The corrective action is to obtain a full 12 to 24 hour curve before any dose change, unless hypoglycemia is suspected, in which case the dose should be reduced immediately.
A second common error is interpreting the glucose nadir without reference to the duration of insulin action. A nadir that occurs early with rapid return to hyperglycemia suggests the insulin duration is too short for the dosing interval, whereas a persistently flat curve above the target range suggests underdosing or insulin resistance. The 2014 review of long-acting glargine and detemir in cats notes that these insulins may require 2 to 4 weeks to reach steady state, and premature dose escalation based on early curves leads to iatrogenic hypoglycemia [clinical use of long-acting glargine and detemir in feline diabetes](https://pubmed.ncbi.nlm.nih.gov/24563492/).
A third error is failing to distinguish true insulin resistance from poor injection technique. Insulin that is injected into fur, into a skin fold, or through a wet needle will not be absorbed reliably. The corrective action is direct observation of the owner's injection technique during a recheck consultation.
## Limitations of Current Evidence
The evidence base for monitoring endocrine therapy in companion animals is strongest for insulin and thyroid hormone, but several areas remain contested. The optimal target glucose range for diabetic cats differs between sources, with some authorities accepting higher nadirs to reduce hypoglycemia risk. The iCatCare guidelines acknowledge that recommendations for monitoring frequency and target ranges are based on expert consensus instead of prospective outcome trials [iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats](https://pubmed.ncbi.nlm.nih.gov/41224734/).
The role of continuous glucose monitoring in routine management is still evolving. While CGM devices provide richer data than intermittent curves, the evidence that they improve glycaemic control or remission rates in cats is limited. Expert opinion differs on whether CGM should replace or supplement traditional blood glucose curves, and on how to interpret sensor lag during rapid glucose changes.
Fructosamine measurement has known limitations in detecting hypoglycemia and in reflecting short-term glycaemic changes. It remains useful as a compliance check and for assessing average control over 2 to 3 weeks, but it cannot guide day-to-day dose adjustments.
## Referral, Consultation, and Escalation
Referral to a specialist is warranted when a diabetic patient fails to stabilize despite appropriate dose adjustments over 4 to 6 weeks, when insulin requirements exceed 1.5 U/kg per dose in dogs or 1 U/kg per dose in cats, or when hypersomatotropism is suspected in cats. Specialist evaluation may include advanced imaging, endogenous insulin or growth hormone assays, and management of concurrent endocrinopathies.
Laboratory involvement is indicated for confirmation of ketonemia, measurement of serial fructosamine, and assessment of concurrent disease. The MSD Veterinary Manual provides species-specific reference intervals and interpretation guidance for endocrine testing [MSD Veterinary Manual professional endocrine reference](https://www.msdvetmanual.com/).
Regulatory reporting obligations vary by jurisdiction. Veterinarians should be aware that adverse drug event reporting, including suspected insulin product failures, may be required in some regions. The AVMA practice resources summarize current professional expectations for adverse event reporting in the United States [AVMA professional practice resources](https://www.avma.org/resources-tools), and the WOAH terrestrial animal health standards address reporting obligations for notifiable diseases that may present with endocrine signs [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/).
| Observation | Likely cause | Discriminating check |
|---|---|---|
| Glucose nadir below range, then sharp rise | Somogyi effect | Full curve or CGM trace, reduce dose, do not increase |
| Flat curve above target range | Underdosing or insulin resistance | Check injection technique, assess intercurrent disease |
| Erratic day-to-day glucose values | Poor insulin handling or injection error | Observe owner technique, check insulin storage |
| Rising insulin requirement over weeks | Hypersomatotropism (cats) or hyperadrenocorticism (dogs) | Endogenous insulin assay, ACTH stimulation, or imaging |
| Clinical hypoglycemia with normal pre-insulin glucose | Rapid insulin absorption or missed meal | Reduce dose, obtain curve to identify nadir timing |
## Frequently Asked Questions
### How Should I Monitor a Diabetic Cat When the Owner Cannot Afford a Continuous Glucose Monitor?
When a continuous glucose monitor is not feasible, return to structured blood glucose curves performed in hospital or by trained owners at home. A minimum of three to five readings across 12 to 24 hours provides adequate information for dose adjustment in most cats. If blood sampling is refused, urine glucose testing offers only a crude estimate and cannot detect hypoglycemia, so it should never be the sole monitoring method. Fructosamine measured every three to four weeks gives a retrospective average and helps confirm overall glycaemic control between curves. The [iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats](https://pubmed.ncbi.nlm.nih.gov/41224734/) emphasize that monitoring intensity should be tailored to the cat, the caregiver, and available resources.
### When Should I Suspect Somogyi Overswing instead of Insulin Resistance?
The Somogyi phenomenon should be suspected when a blood glucose curve shows hypoglycemia followed by rebound hyperglycemia, often with polyuria or polydipsia persisting despite apparent high glucose readings. Insulin resistance is more likely when glucose remains uniformly elevated throughout the curve without any nadir below the reference range. Serial curves are essential because a single curve may miss the nadir. If the nadir is below 3.3 mmol/L in cats or 2.8 mmol/L in dogs, reduce the insulin dose by 10 to 25 percent regardless of subsequent hyperglycemia. The [feline diabetes mellitus review on long-acting glargine and detemir](https://pubmed.ncbi.nlm.nih.gov/24563492/) notes that clinical signs of hypoglycemia may be absent in cats, making curve interpretation the primary diagnostic tool.
### What Is the Minimum Monitoring Protocol for a Stable Diabetic Dog on Maintenance Insulin?
For a stable dog, reassess every two to three months with a physical examination, body weight, owner-reported clinical signs, and a fructosamine concentration. Perform a full blood glucose curve every three to six months or whenever clinical signs change. Owners should maintain a daily log of appetite, water intake, urine output, and any episodes of weakness or collapse. If the dog develops concurrent illness, particularly pancreatitis or renal disease, re-evaluate glycaemic control sooner because insulin requirements can change rapidly. The [MSD Veterinary Manual professional edition](https://www.msdvetmanual.com/) provides species-specific guidance on interpreting clinical signs and laboratory values in the context of ongoing insulin therapy.
### How Do I Explain Monitoring Requirements to a Client Who Expects a Single Test to Confirm Control?
Frame monitoring as a cycle instead of a single event. Explain that each tool answers a different question: the blood glucose curve shows what happens over one day, while fructosamine reflects the previous two to three weeks. Use the analogy of a photograph versus a video. A single glucose reading is a snapshot that can mislead, whereas a curve shows trends. Provide the client with a written schedule that lists which measurements are needed at each visit and what the owner should record at home. The [AVMA practice resources](https://www.avma.org/resources-tools) offer communication frameworks for discussing chronic disease management and setting realistic expectations with clients.
### Should Monitoring Protocols Differ Between Diabetic Dogs and Cats?
Yes. Cats frequently achieve diabetic remission, so the monitoring goal shifts from lifelong dose titration to early recognition of remission and prevention of relapse. Dogs rarely remit and require consistent long-term dosing. Cats are prone to stress hyperglycemia in hospital, so home blood glucose curves are more reliable than in-clinic measurements. Fructosamine is useful in both species but may be less reliable in cats with concurrent hyperthyroidism or acromegaly. The [iCatCare 2025 consensus guidelines](https://pubmed.ncbi.nlm.nih.gov/41224734/) specifically address remission monitoring in cats, including gradual insulin reduction protocols and the role of serial glucose curves in confirming remission.
### How Should I Document Insulin Adjustments to Avoid Errors During Handover or Emergency Visits?
Maintain a dedicated diabetes log within the medical record that includes the insulin type, concentration, dose in units and milliliters, injection timing, and the date and reason for each change. Record the blood glucose curve values in a standardized format with the time of each reading and the time of insulin administration. Note the owner's report of clinical signs separately from your objective measurements. Flag the most recent dose change clearly so that any covering clinician can identify the current regimen without reading the full history. The [Davis-Thompson Foundation veterinary pathology resources](https://www.davisthompsonfoundation.org/) emphasize structured documentation as a core component of diagnostic accuracy and case continuity across providers.
## Related Clinical & Scientific Guides
* [Hypersensitivity Reactions: Types and Mechanisms](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/hypersensitivity-reactions-types-and-mechanisms)
* [Therapeutic Decision-Making for Respiratory Infections in Cattle](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/therapeutic-decision-making-respiratory-infections-cattle)
* [Monitoring Fluid Therapy in Critically Ill Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/monitoring-fluid-therapy-critically-ill-veterinary)
## References and Further Reading
- [iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats.](https://pubmed.ncbi.nlm.nih.gov/41224734/). 2025.
- [Peptide-mediated targeting of the islets of Langerhans.](https://pubmed.ncbi.nlm.nih.gov/15983211/). 2005.
- [Management of iron overload: lessons from transfusion-dependent hemoglobinopathies.](https://pubmed.ncbi.nlm.nih.gov/39293029/). 2025.
- [Feline diabetes mellitus: clinical use of long-acting glargine and detemir.](https://pubmed.ncbi.nlm.nih.gov/24563492/). 2014.
- [Clinical applications of blood cell ratios in veterinary hematology: From diagnosis to prognosis.](https://pubmed.ncbi.nlm.nih.gov/41907451/). 2026.
- [The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review.](https://pubmed.ncbi.nlm.nih.gov/32229068/). 2021.
- [Davis-Thompson Foundation Veterinary Pathology Resources](https://www.davisthompsonfoundation.org/). Davis-Thompson Foundation.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.
- [American Veterinary Medical Association Practice Resources](https://www.avma.org/resources-tools). American Veterinary Medical Association.
## Related Articles
- [Monitoring Immunosuppressive Therapy in Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/monitoring-immunosuppressive-therapy-veterinary)
- [Monitoring Fluid Therapy in Critically Ill Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/monitoring-fluid-therapy-critically-ill-veterinary)
- [Monitoring Analgesic Therapy in Horses: A Practical Guide](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/monitoring-analgesic-therapy-horses-practical-guide)
- [Monitoring Corticosteroid Therapy in Veterinary Dermatology](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/monitoring-corticosteroid-therapy-veterinary-dermatology)
- [Decision Framework for Anticoagulant Therapy in Veterinary Patients](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/decision-framework-anticoagulant-therapy-veterinary)
> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.